<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>FDA novel drug approvals</title>
    <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
    <description>Events collected by UnlimitedPipe 0.10.62</description>
    <generator>UnlimitedPipe 0.10.62</generator>
    <lastBuildDate>Mon, 16 Nov 2026 18:16:27 +0000</lastBuildDate>
    <item>
      <title>FDA approves Klygefa (gefurulimab-gaks) to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">0958ef2f759b36270087</guid>
      <pubDate>Fri, 13 Nov 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 11/13/2026: Klygefa (gefurulimab-gaks) to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.</description>
    </item>
    <item>
      <title>FDA approves Pimjetmi (pimicotinib) to treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">0b6033225a200c4fe55d</guid>
      <pubDate>Fri, 13 Nov 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 11/13/2026: Pimjetmi (pimicotinib) to treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity.</description>
    </item>
    <item>
      <title>FDA approves Sunharbo (asundexian) to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">738d45baf545bf8d057c</guid>
      <pubDate>Mon, 09 Nov 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 11/9/2026: Sunharbo (asundexian) to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.</description>
    </item>
    <item>
      <title>FDA approves Hibsago (bepirovirsen) to treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">94023d4e3df7151260c9</guid>
      <pubDate>Tue, 20 Oct 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 10/20/2026: Hibsago (bepirovirsen) to treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy.</description>
    </item>
    <item>
      <title>FDA approves Hovilpri (pritelivir) to treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">265a5b1fe0cf959b0410</guid>
      <pubDate>Fri, 09 Oct 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 10/9/2026: Hovilpri (pritelivir) to treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies.</description>
    </item>
    <item>
      <title>FDA approves Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">29044f8cc5233380cb2a</guid>
      <pubDate>Mon, 28 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/28/2026: Emcitate (tiratricol) to treat peripheral thyrotoxicosis in patients with MCT8 deficiency.</description>
    </item>
    <item>
      <title>FDA approves Atebrioz (zilurgisertib) to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">f3f2db50f295e4620b81</guid>
      <pubDate>Fri, 25 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/25/2026: Atebrioz (zilurgisertib) to reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva.</description>
    </item>
    <item>
      <title>FDA approves Juvmo (tavapadon) to treat Parkinson’s disease in adults</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">bbcad89f0abfdb0ce123</guid>
      <pubDate>Fri, 25 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/25/2026: Juvmo (tavapadon) to treat Parkinson’s disease in adults.</description>
    </item>
    <item>
      <title>FDA approves Lyrfigtu (lirafugratinib) for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">278e7116d5b7d4cfef42</guid>
      <pubDate>Wed, 23 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/23/2026: Lyrfigtu (lirafugratinib) for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement.</description>
    </item>
    <item>
      <title>FDA approves Onswik (insulin efsitora alfa-gobe) to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">a635f5b10e9f4acface5</guid>
      <pubDate>Wed, 23 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/23/2026: Onswik (insulin efsitora alfa-gobe) to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.</description>
    </item>
    <item>
      <title>FDA approves Pixclara (floretyrosine F 18) to use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">1ef03dbdae492fbcc86c</guid>
      <pubDate>Fri, 11 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/11/2026: Pixclara (floretyrosine F 18) to use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations.</description>
    </item>
    <item>
      <title>FDA approves Isembyld (apitegromab-mstn) to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">b9ae0b97ab6a485a396b</guid>
      <pubDate>Fri, 11 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/11/2026: Isembyld (apitegromab-mstn) to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment.</description>
    </item>
    <item>
      <title>FDA approves Etcamah (camizestrant) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">dcb80a68bbf5d9ff84d8</guid>
      <pubDate>Fri, 04 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/4/2026: Etcamah (camizestrant) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy.</description>
    </item>
    <item>
      <title>FDA approves Zanvastro (zilganersen) to treat Alexander disease in pediatric and adult patients</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">e866f2314e7c5aaca84b</guid>
      <pubDate>Thu, 03 Sep 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 9/3/2026: Zanvastro (zilganersen) to treat Alexander disease in pediatric and adult patients.</description>
    </item>
    <item>
      <title>FDA approves Mimrylo (rusfertide) to treat erythrocytosis in adults with polycythemia vera</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">dc253e1141a9212348ed</guid>
      <pubDate>Fri, 28 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/28/2026: Mimrylo (rusfertide) to treat erythrocytosis in adults with polycythemia vera.</description>
    </item>
    <item>
      <title>FDA approves Lisraya (brepocitinib) to treat dermatomyositis in adults</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">0a29d3774254aa74d946</guid>
      <pubDate>Thu, 27 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/27/2026: Lisraya (brepocitinib) to treat dermatomyositis in adults.</description>
    </item>
    <item>
      <title>FDA approves Rasonque (daraxonrasib) to treat metastatic pancreatic cancer</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">d273401a08340a485b54</guid>
      <pubDate>Wed, 26 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/26/2026: Rasonque (daraxonrasib) to treat metastatic pancreatic cancer.</description>
    </item>
    <item>
      <title>FDA approves Pasatru (garetosmab-grts) to reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">5aa87a0fc9ff4d93e5f2</guid>
      <pubDate>Wed, 19 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/19/2026: Pasatru (garetosmab-grts) to reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva.</description>
    </item>
    <item>
      <title>FDA approves Zenbexus (iberdomide) to be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">e822fe516998998dd50d</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/13/2026: Zenbexus (iberdomide) to be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.</description>
    </item>
    <item>
      <title>FDA approves Tauklarify (florquinitau F 18) to be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">083939f0d51097db39bf</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/13/2026: Tauklarify (florquinitau F 18) to be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology.</description>
    </item>
    <item>
      <title>FDA approves Orzeyful (oveporexton) to treat narcolepsy type 1</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">c2298d2450cbf0848b49</guid>
      <pubDate>Wed, 05 Aug 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 8/5/2026: Orzeyful (oveporexton) to treat narcolepsy type 1.</description>
    </item>
    <item>
      <title>FDA approves Simtriyo (centanafadine) to treat attention-deficit hyperactivity disorder</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">db41d78d60053e49d637</guid>
      <pubDate>Fri, 24 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/24/2026: Simtriyo (centanafadine) to treat attention-deficit hyperactivity disorder.</description>
    </item>
    <item>
      <title>FDA approves Lytenava (bevacizumab-vikg) to treat patients with neovascular (wet) age-related macular degeneration</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">40ab2dce4307f19f79a0</guid>
      <pubDate>Fri, 24 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/24/2026: Lytenava (bevacizumab-vikg) to treat patients with neovascular (wet) age-related macular degeneration.</description>
    </item>
    <item>
      <title>FDA approves Jideytro (zidesamtinib) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">485c78e39068203f1669</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/22/2026: Jideytro (zidesamtinib) to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor.</description>
    </item>
    <item>
      <title>FDA approves Lipfendra (enlicitide decanoate) to reduce low-density lipoprotein cholesterol</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">2386e2602ce8e5970d69</guid>
      <pubDate>Wed, 15 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/15/2026: Lipfendra (enlicitide decanoate) to reduce low-density lipoprotein cholesterol.</description>
    </item>
    <item>
      <title>FDA approves Revtorpyk (gedatolisib) In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">feb553c7ea78d5292779</guid>
      <pubDate>Tue, 14 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/14/2026: Revtorpyk (gedatolisib) In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.</description>
    </item>
    <item>
      <title>FDA approves Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">28ef20ce8d0f08862709</guid>
      <pubDate>Tue, 07 Jul 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 7/7/2026: Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.</description>
    </item>
    <item>
      <title>FDA approves Lumvoa (veligrotug-vvze) to treat thyroid eye disease</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">439649a1d3453c9a1653</guid>
      <pubDate>Fri, 26 Jun 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 6/26/2026: Lumvoa (veligrotug-vvze) to treat thyroid eye disease.</description>
    </item>
    <item>
      <title>FDA approves Utebzi (tebipenem pivoxil) to treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">2dcd667cbe0f92e12f11</guid>
      <pubDate>Wed, 17 Jun 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 6/17/2026: Utebzi (tebipenem pivoxil) to treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options.</description>
    </item>
    <item>
      <title>FDA approves Ambelvist (gadoquatrane) to detect and visualize lesions with abnormal vascularity, in conjunction with MRI</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">1b1a2c2ca325c2a839a6</guid>
      <pubDate>Fri, 12 Jun 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 6/12/2026: Ambelvist (gadoquatrane) to detect and visualize lesions with abnormal vascularity, in conjunction with MRI.</description>
    </item>
    <item>
      <title>FDA approves Cypsedo (cipepofol) to induce general anesthesia in adults undergoing surgery</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">2ab0e08300e8100fe6a6</guid>
      <pubDate>Fri, 29 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/29/2026: Cypsedo (cipepofol) to induce general anesthesia in adults undergoing surgery.</description>
    </item>
    <item>
      <title>FDA approves Xocova (ensitrelvir) to use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">052bc057d6f214328d88</guid>
      <pubDate>Fri, 29 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/29/2026: Xocova (ensitrelvir) to use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19.</description>
    </item>
    <item>
      <title>FDA approves Zaynich (cefepime and zidebactam) to treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">2207e79591b3dea9065b</guid>
      <pubDate>Fri, 29 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/29/2026: Zaynich (cefepime and zidebactam) to treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms.</description>
    </item>
    <item>
      <title>FDA approves Decnupaz (pivekimab sunirine-pvzy) to treat adults with blastic plasmacytoid dendritic cell neoplasm Drug Trials Snapshot</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">b99e517f51189363228a</guid>
      <pubDate>Wed, 27 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/27/2026: Decnupaz (pivekimab sunirine-pvzy) to treat adults with blastic plasmacytoid dendritic cell neoplasm Drug Trials Snapshot.</description>
    </item>
    <item>
      <title>FDA approves Hepcludex (bulevirtide-gmod) to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">5ed757f253b6ad7bc753</guid>
      <pubDate>Fri, 22 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/22/2026: Hepcludex (bulevirtide-gmod) to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis.</description>
    </item>
    <item>
      <title>FDA approves Baxfendy (baxdrostat) to treat hypertension in combination with other antihypertensive drugs</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">d688336820a348c47ea8</guid>
      <pubDate>Fri, 15 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/15/2026: Baxfendy (baxdrostat) to treat hypertension in combination with other antihypertensive drugs.</description>
    </item>
    <item>
      <title>FDA approves Beqalzi (sonrotoclax) to treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">1b27c6a863c7994c0777</guid>
      <pubDate>Wed, 13 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/13/2026: Beqalzi (sonrotoclax) to treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor.</description>
    </item>
    <item>
      <title>FDA approves Veppanu (vepdegestrant) to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">2b10d53ba45ca4f5df30</guid>
      <pubDate>Fri, 01 May 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 5/1/2026: Veppanu (vepdegestrant) to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.</description>
    </item>
    <item>
      <title>FDA approves Idvynso (doravirine and islatravir) to treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">abe165072951ad8f9771</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 4/20/2026: Idvynso (doravirine and islatravir) to treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.</description>
    </item>
    <item>
      <title>FDA approves Foundayo (orforglipron) to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">9043ddfd6edb064e662c</guid>
      <pubDate>Wed, 01 Apr 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 4/1/2026: Foundayo (orforglipron) to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.</description>
    </item>
    <item>
      <title>FDA approves Awiqli (insulin icodec-abae) to improve glycemic control in adults with type 2 diabetes mellitus</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">d044fccbcefafe8a263b</guid>
      <pubDate>Thu, 26 Mar 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 3/26/2026: Awiqli (insulin icodec-abae) to improve glycemic control in adults with type 2 diabetes mellitus.</description>
    </item>
    <item>
      <title>FDA approves Lifyorli (relacorilant) to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">83835552493f80812f78</guid>
      <pubDate>Wed, 25 Mar 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 3/25/2026: Lifyorli (relacorilant) to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab.</description>
    </item>
    <item>
      <title>FDA approves Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">1347676c44ab749554c8</guid>
      <pubDate>Tue, 24 Mar 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 3/24/2026: Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).</description>
    </item>
    <item>
      <title>FDA approves Icotyde (icotrokinra) to treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy…</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">45377a4db051322eb842</guid>
      <pubDate>Tue, 17 Mar 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 3/17/2026: Icotyde (icotrokinra) to treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy Drug Trials Snapshot.</description>
    </item>
    <item>
      <title>FDA approves Lynavoy (linerixibat) to treat cholestatic pruritus associated with primary biliary cholangitis</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">d5957fa39d3d1e153e46</guid>
      <pubDate>Tue, 17 Mar 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 3/17/2026: Lynavoy (linerixibat) to treat cholestatic pruritus associated with primary biliary cholangitis.</description>
    </item>
    <item>
      <title>FDA approves Yuviwel (navepegritide) to increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">c3a322801d80f2290099</guid>
      <pubDate>Fri, 27 Feb 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 2/27/2026: Yuviwel (navepegritide) to increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses.</description>
    </item>
    <item>
      <title>FDA approves Loargys (pegzilarginase-nbln) to treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">b2e3af2225729f3baf2c</guid>
      <pubDate>Mon, 23 Feb 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 2/23/2026: Loargys (pegzilarginase-nbln) to treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction.</description>
    </item>
    <item>
      <title>FDA approves Bysanti (milsaperidone) to treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">6dcde7c0a5902d01beae</guid>
      <pubDate>Fri, 20 Feb 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 2/20/2026: Bysanti (milsaperidone) to treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder.</description>
    </item>
    <item>
      <title>FDA approves Adquey (difamilast) to treat mild to moderate atopic dermatitis</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">aa833e5612264850dc35</guid>
      <pubDate>Thu, 12 Feb 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 2/12/2026: Adquey (difamilast) to treat mild to moderate atopic dermatitis.</description>
    </item>
    <item>
      <title>FDA approves Zycubo (copper histidinate) to treat Menkes disease Drug Trials Snapshot</title>
      <link>https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>
      <guid isPermaLink="false">3763a42bbfc450c0421f</guid>
      <pubDate>Mon, 12 Jan 2026 00:00:00 +0000</pubDate>
      <description>Novel drug approval of 1/12/2026: Zycubo (copper histidinate) to treat Menkes disease Drug Trials Snapshot.</description>
    </item>
  </channel>
</rss>
